Undifferentiated Ovarian Carcinoma Completed Phase 1 Trials for Motolimod (DB12303)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01294293TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerTreatment